pvsripo

Vaccineexperimental

Clinical trial activity

9 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2017 (NCT03043391)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • pvsripo

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04690699Phase 1/Phase 2 (Phase 2)Aug 1, 2021Istari Oncology, Inc.
NCT04577807Phase 2Nov 17, 2020Istari Oncology, Inc.
NCT04479241Phase 2Oct 21, 2020Istari Oncology, Inc.
NCT04125719Phase 1Dec 1, 2019Bristol-Myers Squibb, Duke University, Istari Oncology, Inc.
NCT03973879Phase 1/Phase 2 (Phase 2)Aug 1, 2019Duke University, Genentech, Istari Oncology, Inc.
NCT03712358Phase 1Nov 26, 2018Duke University, Istari Oncology, Inc.
NCT03564782Early Phase 1 (Phase 1)Sep 24, 2018Department of Defense, Duke University, Istari Oncology, Inc.
NCT03043391Phase 1Jul 1, 2017Duke University, Musella Foundation, The Andrew McDonough B+ Foundation
NCT04599647N/AIstari Oncology, Inc.
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Istari Oncology, Inc.For profit8632018
Duke UniversityAcademic/Hospital5322017
Bristol-Myers SquibbFor profit1012019
Department of DefenseGovernment1012018
GenentechFor profit1012019
Musella FoundationAcademic/Hospital1012017
The Andrew McDonough B+ FoundationAcademic/Hospital1012017
7 organizations
Page 1 / 1